{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:59:29Z","timestamp":1790773169631,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.neuroscience.2026.08.042","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:57:54Z","timestamp":1787673474000},"page":"144-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["K16ApoE-mediated delivery across the blood\u2013brain barrier: mechanisms, applications, and translational challenges"],"prefix":"10.1016","volume":"615","author":[{"given":"Sengodan","family":"Amudha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivaraj","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8489-531X","authenticated-orcid":false,"given":"Israel V.M.V.","family":"Enoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.neuroscience.2026.08.042_b0005","article-title":"P13.04 K16ApoE increases drug-delivery across the blood brain barrier in an animal model of brain metastases","volume":"19","author":"Aasen","year":"2017","journal-title":"Neuro Oncol."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.08.042_b0010","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/1535-7163.MCT-19-0160","article-title":"Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood-brain barrier","volume":"18","author":"Aasen","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.08.042_b0015","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70016","article-title":"Beyond efficacy: ensuring safety in peptide therapeutics through immunogenicity assessment","volume":"31","author":"Achilleos","year":"2025","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1347987","article-title":"The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets","volume":"16","author":"Adamu","year":"2024","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.08.042_b0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00415-024-12770-x","article-title":"An update on immune-based alpha-synuclein trials in Parkinson's disease","volume":"272","author":"Alfaidi","year":"2024","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.08.042_b0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/jpm15090437","article-title":"Anti-amyloid monoclonal antibodies for Alzheimer's disease: evidence, ARIA risk, and precision patient selection","volume":"15","author":"Alkhalifa","year":"2025","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0035","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/s41416-025-03325-6","article-title":"Efficacy and safety of low- and high-intensity focused ultrasound in glioblastoma: a systematic review of preclinical and clinical studies","volume":"134","author":"Alrashidi","year":"2026","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature09522","article-title":"Pericytes regulate the blood\u2013brain barrier","volume":"468","author":"Armulik","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neuroscience.2026.08.042_b0045","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213817","article-title":"Metachromatic leukodystrophy: new therapy advancements and emerging research directions","volume":"105","author":"Asbreuk","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113595","article-title":"Mechanisms of receptor-mediated transcytosis at the blood-brain barrier","volume":"381","author":"Baghirov","year":"2025","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.neuroscience.2026.08.042_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101587","article-title":"Elevated tripeptidyl-peptidase 1 corrects multiple disease phenotypes in a mouse model of juvenile neuronal ceroid lipofuscinosis","volume":"33","author":"Banach-Petrosky","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.08.042_b0060","article-title":"The penetration of therapeutics across the blood-brain barrier: classic case studies and clinical implications","volume":"5","author":"Banks","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0065","article-title":"Lysosomal storage diseases in North America: a comprehensive review of enzyme therapies and unmet needs","volume":"6","author":"Bennett","year":"2025","journal-title":"Ther. Adv. Rare Dis."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2026.100299","article-title":"Emerging frontiers of responsive nanomaterials in drug delivery systems: from design to clinical translation","author":"Bhairam","year":"2026","journal-title":"OpenNano"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0075","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/296151","article-title":"The Trojan horse liposome technology for nonviral gene transfer across the blood-brain barrier","volume":"2011","author":"Boado","year":"2011","journal-title":"J. Drug Deliv."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.08.042_b0080","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16324","article-title":"Ceroid lipofuscinosis type 2 disease: effective presymptomatic therapy-oldest case of a presymptomatic enzyme therapy","volume":"31","author":"Breuillard","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0085","first-page":"468","article-title":"K16ApoE enhances a \u03b2-associated 11C-PiB deposition and PET signal in APP\/PS1 transgenic mice","volume":"9","author":"Brown","year":"2019","journal-title":"J. Alzheimers Dis. Parkinsonism"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0090","article-title":"Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: a case series","volume":"36","author":"Chan","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12987-024-00563-3","article-title":"Blood-brain barrier disruption: a culprit of cognitive decline?","volume":"21","author":"Che","year":"2024","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0100","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/4482931","article-title":"The blood-brain barrier in both humans and rats: a perspective from 3D imaging","volume":"2024","author":"Chen","year":"2024","journal-title":"Int. J. Biomed. Imaging"},{"issue":"17","key":"10.1016\/j.neuroscience.2026.08.042_b0105","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.3390\/nu16172947","article-title":"Impact of peptide transport and memory function in the brain","volume":"16","author":"Cheng","year":"2024","journal-title":"Nutrients"},{"issue":"24","key":"10.1016\/j.neuroscience.2026.08.042_b0110","doi-asserted-by":"crossref","first-page":"13456","DOI":"10.3390\/ijms222413456","article-title":"Mucopolysaccharidosis type VI, an updated overview of the disease","volume":"22","author":"D'Avanzo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0125","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202502315","article-title":"Nanoparticle therapeutics in clinical perspective: classification, marketed products, and regulatory landscape","volume":"21","author":"Desai","year":"2025","journal-title":"Small"},{"issue":"11","key":"10.1016\/j.neuroscience.2026.08.042_b0130","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.3390\/ijms25115601","article-title":"The basic requirement of tight junction proteins in blood-brain barrier function and their role in pathologies","volume":"25","author":"Dithmer","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.neuroscience.2026.08.042_b0135","doi-asserted-by":"crossref","first-page":"11541","DOI":"10.3390\/ijms262311541","article-title":"Modulating cerebrospinal fluid composition in neurodegenerative processes: modern drug delivery and clearance strategies","volume":"26","author":"Dutysheva","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.559804","article-title":"CNS-targeting therapies for lysosomal storage diseases: current advances and challenges","volume":"7","author":"Edelmann","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.08.042_b0145","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jimd.12615","article-title":"Advances in therapies for neurological lysosomal storage disorders","volume":"46","author":"Ellison","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0150","doi-asserted-by":"crossref","first-page":"100.e1","DOI":"10.1016\/j.jtct.2025.09.023","article-title":"Efficacy and safety of allogeneic hematopoietic stem cell transplantation in curing sickle cell disease: a systematic review and meta-analysis of single-arm studies","volume":"32","author":"Folarin","year":"2026","journal-title":"Transplant. Cell Ther."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.08.042_b0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12987-026-00760-2","article-title":"Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain","volume":"23","author":"Gampa","year":"2026","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0160","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic stem- and progenitor-cell gene therapy for hurler syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.08.042_b0165","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/pharmaceutics15071999","article-title":"Cell-penetrating and targeted peptides delivery systems as potential pharmaceutical carriers for enhanced delivery across the blood\u2013brain barrier (BBB)","volume":"15","author":"Ghorai","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.neuroscience.2026.08.042_b0170","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jacbts.2023.03.013","article-title":"High-throughput microscopy characterization of rare LDLR variants","volume":"8","author":"Gra\u00e7a","year":"2023","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0175","article-title":"Brain-targeted delivery of siRNA via non-viral delivery systems, the therapeutic strategy for Alzheimer's disease-unveiling challenges and prospects","volume":"11","author":"Gu","year":"2026","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1360302","article-title":"Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria","volume":"4","author":"Haqqani","year":"2024","journal-title":"Front. Drug Deliv."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.08.042_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2019.165614","article-title":"The contribution of multicellular model organisms to neuronal ceroid lipofuscinosis research","volume":"1866","author":"Huber","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102481","article-title":"Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: breaking the memory barrier","volume":"101","author":"Kamatham","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0195","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","article-title":"AAV vectors applied to the treatment of CNS disorders: clinical status and challenges","volume":"355","author":"Kang","year":"2023","journal-title":"J. Control. Release"},{"issue":"30","key":"10.1016\/j.neuroscience.2026.08.042_b0200","doi-asserted-by":"crossref","first-page":"32544","DOI":"10.1021\/acsomega.5c00364","article-title":"Overcoming the blood-brain barrier for drug delivery to the brain","volume":"10","author":"Katz","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.omtm.2023.05.010","article-title":"Enzyme replacement with transferrin receptor-targeted \u03b1-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice","volume":"29","author":"Kida","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0210","doi-asserted-by":"crossref","unstructured":"Kie\u0107-Wilk, B., Guijt, P., Dan, M., Abdelwahab, M., Revel-Vilk, S., Serratrice, C., International Gaucher Alliance (IGA) and the International Working Group on Gaucher Disease (IWGGD), 2025. Home enzyme replacement therapy in Gaucher disease: A review. J. Clin. Med. 14 (3), 842. doi: 10.3390\/jcm14030842.","DOI":"10.3390\/jcm14030842"},{"issue":"4","key":"10.1016\/j.neuroscience.2026.08.042_b0215","doi-asserted-by":"crossref","first-page":"256","DOI":"10.13104\/imri.2022.26.4.256","article-title":"Dynamic contrast-enhanced MRI and its applications in various central nervous system diseases","volume":"26","author":"Kim","year":"2022","journal-title":"Investig. Magn. Reson. Imaging"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.08.042_b0220","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0225","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addr.2021.03.002","article-title":"Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues","volume":"173","author":"Kouzehgarani","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0240","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.apsb.2025.10.026","article-title":"Progress in peptide and protein therapeutics: challenges and strategies","volume":"15","author":"Liu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.neuroscience.2026.08.042_b0245","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/cimb47121009","article-title":"Mapping lysosomal storage disorders with neurological features by cellular pathways: towards precision medicine","volume":"47","author":"Makridou","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.08.042_b0250","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/ijms23041999","article-title":"Innate immunity in mucopolysaccharide diseases","volume":"23","author":"Mandolfo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.08.042_b0255","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1730346","article-title":"Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products","volume":"16","author":"Mattei","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.08.042_b0265","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/mt.2013.267","article-title":"Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain","volume":"22","author":"Meng","year":"2014","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.08.042_b0270","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ymthe.2017.03.037","article-title":"A basic ApoE-based peptide mediator to deliver proteins across the blood-brain barrier: long-term efficacy, toxicity, and mechanism","volume":"25","author":"Meng","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1396520","article-title":"The complement system in neurodegenerative and inflammatory diseases of the central nervous system","volume":"15","author":"Negro-Demontel","year":"2024","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.08.042_b0280","first-page":"194","article-title":"Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"J. Pediatr. Pharmacol. Ther."},{"issue":"16","key":"10.1016\/j.neuroscience.2026.08.042_b0285","doi-asserted-by":"crossref","first-page":"12931","DOI":"10.3390\/ijms241612931","article-title":"Peptide-based agents for cancer treatment: current applications and future directions","volume":"24","author":"Nh\u00e0n","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.08.042_b0290","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/biomedicines12040851","article-title":"Transcytosis-driven treatment of neurodegenerative disorders by mRNA-expressed antibody\u2013transferrin conjugates","volume":"12","author":"Niazi","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0295","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jcpt.12136","article-title":"Current and potential therapeutic strategies for mucopolysaccharidoses","volume":"39","author":"Noh","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"issue":"6","key":"10.1016\/j.neuroscience.2026.08.042_b0300","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/pharmaceutics14061283","article-title":"A historical review of brain drug delivery","volume":"14","author":"Pardridge","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.neuroscience.2026.08.042_b0305","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1021\/acs.molpharmaceut.2c00523","article-title":"Peptides as pharmacological carriers to the brain: promises, shortcomings and challenges","volume":"19","author":"Parrasia","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115657","article-title":"Convection-enhanced delivery for brain malignancies: technical parameters, formulation strategies and clinical perspectives","volume":"224","author":"Parvar","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.08.042_b0315","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/pharmaceutics14122719","article-title":"Current update on transcellular brain drug delivery","volume":"14","author":"Pawar","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.neuroscience.2026.08.042_b0320","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v8i2.2045","article-title":"A cure for Sanfilippo syndrome? A summary of current therapeutic approaches and their promise","volume":"8","author":"Pearse","year":"2020","journal-title":"Med. Res. Arch."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2025.214585","article-title":"Liposomes: recent progress on nanoparticles production and their usage in medicine","volume":"180","author":"Peru\u0161","year":"2026","journal-title":"Biomater. Adv."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.08.042_b0330","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s43856-024-00703-8","article-title":"Bone marrow transplantation reverses metabolic alterations in multiple sulfatase deficiency: a case series","volume":"5","author":"Pillai","year":"2025","journal-title":"Commun. Med."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.08.042_b0335","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/cancers16010236","article-title":"Breaking barriers in neuro-oncology: a scoping literature review on invasive and non-invasive techniques for blood-brain barrier disruption","volume":"16","author":"Pinkiewicz","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.neuroscience.2026.08.042_b0340","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.3390\/ijms26157050","article-title":"Beyond the walls of troy: a scoping review on pharmacological strategies to enhance drug delivery across the blood\u2013brain barrier and blood\u2013tumor barrier","volume":"26","author":"Pinkiewicz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.08.042_b0345","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/pharmaceutics14030588","article-title":"Strategies to improve drug strength in nasal preparations for brain delivery of low aqueous solubility drugs","volume":"14","author":"Pires","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0350","doi-asserted-by":"crossref","DOI":"10.26599\/NR.2025.94907916","article-title":"Peptide-based brain distribution improvement strategies for nano delivery systems in CNS diseases treatment","volume":"18","author":"Qian","year":"2025","journal-title":"Nano Res."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.08.042_b0355","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/antib12040074","article-title":"The role of antibody-based therapies in neuro-oncology","volume":"12","author":"Ramapriyan","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0360","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.stem.2025.10.014","article-title":"The evolution of microglia replacement: a new paradigm for CNS disease therapy","volume":"32","author":"Rao","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0365","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1007049806660","article-title":"Osmotic opening of the blood\u2013brain barrier: principles, mechanism, and therapeutic applications","volume":"20","author":"Rapoport","year":"2000","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0370","series-title":"Agency for Healthcare Research and Quality (US), Rockville (MD)","article-title":"Enzyme-replacement therapies for lysosomal storage diseases","author":"Ratko","year":"2013"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0375","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.apha.2014.06.004","article-title":"Delivery of therapeutic peptides and proteins to the CNS","volume":"71","author":"Salameh","year":"2014","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0380","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"issue":"Suppl 5","key":"10.1016\/j.neuroscience.2026.08.042_b0385","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nov212.18","article-title":"DDEL-18: evidence the transporter peptide, K16ApoE, transiently opens the blood-brain barrier to allow passage of molecules to the brain","volume":"17","author":"Sarkar","year":"2015","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.08.042_b0395","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.3390\/biomedicines13092167","article-title":"Intrathecal therapies for neurodegenerative diseases: a review of current approaches and the urgent need for advanced delivery systems","volume":"13","author":"Schreiner","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0400","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jconrel.2022.08.051","article-title":"Recent advances in drug delivery and targeting to the brain","volume":"350","author":"Sethi","year":"2022","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.08.042_b0405","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13578-023-01079-3","article-title":"Cutting-edge advances in modeling the blood-brain barrier and tools for its reversible permeabilization for enhanced drug delivery into the brain","volume":"13","author":"Sharma","year":"2023","journal-title":"Cell Biosci."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114018","article-title":"Low-frequency ultrasound-mediated blood-brain barrier opening enables non-invasive lipid nanoparticle RNA delivery to glioblastoma","volume":"385","author":"Shumer-Elbaz","year":"2025","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.neuroscience.2026.08.042_b0420","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.3390\/pharmaceutics14112425","article-title":"Protein and gene delivery systems for neurodegenerative disorders: where do we stand today?","volume":"14","author":"Siafaka","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118516","article-title":"Interactions between astrocytes and cerebral endothelial cells in central nervous system diseases","volume":"191","author":"Sun","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0430","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s13346-025-01840-w","article-title":"Peptide-functionalized nanoparticles for brain-targeted therapeutics","volume":"16","author":"Tang","year":"2026","journal-title":"Drug Deliv. Transl. Res."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.08.042_b0435","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14712598.2025.2606047","article-title":"From trial to transformation: insights into hematopoietic stem cell-gene therapy for Hurler syndrome","volume":"25","author":"Tucci","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.08.042_b0440","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40139-015-0086-y","article-title":"Mouse models as predictors of human responses: evolutionary medicine","volume":"3","author":"Uhl","year":"2015","journal-title":"Curr. Pathobiol. Rep."},{"issue":"10","key":"10.1016\/j.neuroscience.2026.08.042_b0445","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.7150\/thno.69682","article-title":"Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy","volume":"12","author":"Upton","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.08.042_b0450","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic approaches targeting amyloid-\u03b2, \u03b1-synuclein, and tau for the treatment of neurodegenerative disorders","volume":"13","author":"Valera","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105673","article-title":"Neuropathic pain, mood, and stress-related disorders: a literature review of comorbidity and co-pathogenesis","volume":"161","author":"Vieira","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.08.042_b0460","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/pharmaceutics16020240","article-title":"Peptide-mediated nanocarriers for targeted drug delivery: developments and strategies","volume":"16","author":"Wang","year":"2024","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.neuroscience.2026.08.042_b0465","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3390\/pharmaceutics13111980","article-title":"Modulating the blood\u2013brain barrier: a comprehensive review","volume":"13","author":"Whelan","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0470","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.omtm.2017.01.004","article-title":"Chronic enzyme replacement to the brain of a late infantile neuronal ceroid lipofuscinosis mouse has differential effects on phenotypes of disease","volume":"4","author":"Wiseman","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"23","key":"10.1016\/j.neuroscience.2026.08.042_b0480","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.3390\/nano13233004","article-title":"Recent uses of lipid nanoparticles, cell-penetrating and bioactive peptides for the development of brain-targeted nanomedicines against neurodegenerative disorders","volume":"13","author":"Wu","year":"2023","journal-title":"Nanomaterials"},{"key":"10.1016\/j.neuroscience.2026.08.042_b0475","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Sig. Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.08.042_b0485","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/svn-2018-000198","article-title":"Basement membrane and blood\u2013brain barrier","volume":"4","author":"Xu","year":"2019","journal-title":"Stroke Vasc. Neurol."},{"issue":"8","key":"10.1016\/j.neuroscience.2026.08.042_b0490","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3390\/pharmaceutics17081041","article-title":"Overcoming the blood-brain barrier: advanced strategies in targeted drug delivery for neurodegenerative diseases","volume":"17","author":"Yang","year":"2025","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.neuroscience.2026.08.042_b0495","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/17425247.2025.2545878","article-title":"Infusion-based drug delivery to the brain: what\u2019s next?","volume":"22","author":"Yuan","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.08.042_b0500","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.3390\/ijms23126788","article-title":"Laminin as a biomarker of blood-brain barrier disruption under neuroinflammation: a systematic review","volume":"23","author":"Zapata-Acevedo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0505","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Sig. Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.08.042_b0510","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70261","article-title":"Neuronal ceroid lipofuscinosis-concepts, classification, and avenues for therapy","volume":"31","author":"Zhang","year":"2025","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuroscience.2026.08.042_b0515","first-page":"1878","article-title":"Poly(\u03b1-l-lysine)-based nanomaterials for versatile biomedical applications: current advances and perspectives","volume":"6","author":"Zheng","year":"2021","journal-title":"Bioact. Mater."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.08.042_b0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.2020.01011","article-title":"A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management","volume":"9","author":"Zhou","year":"2020","journal-title":"Intractable Rare Dis. Res."},{"issue":"8","key":"10.1016\/j.neuroscience.2026.08.042_b0525","doi-asserted-by":"crossref","DOI":"10.1063\/5.0284305","article-title":"Material considerations for delivering therapeutics across the blood\u2013brain barrier","volume":"13","author":"Zoba","year":"2025","journal-title":"APL Mater."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226005853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226005853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:21:00Z","timestamp":1790770860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226005853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":99,"alternative-id":["S0306452226005853"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.08.042","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"K16ApoE-mediated delivery across the blood\u2013brain barrier: mechanisms, applications, and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.08.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}